First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more 2021 The Lancet 2580 citations